Investing In NovaBay Pharmaceuticals Inc. (AMEX: NBY): Why Should You?

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for NovaBay Pharmaceuticals Inc. (NBY) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by +$0.0101, or +3.61%, to $0.29. Volume reached 313,226 shares, with price reaching a high of $0.299 and a low of $0.272. Earlier, Yahoo Finance discussed this stock as it revealed NovaBay Pharmaceuticals to Hold Second Quarter 2022 Conference Call on August 11.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Stocks Info

The company is listed on the AMEX and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $0.28 and fluctuated between $0.2890 as its day high and $0.2512 as its day low. The current market capitalization of NovaBay Pharmaceuticals Inc. is $13.53M. A total of 1.06 million shares were traded on the day, compared to an average of 638.52K shares.

Insider Activity

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, NBY has seen 4 BUY and 0 SELL insider trades, representing the acquisition of 120,000 and the disposition of 0 shares. Over the last 12 months, there were 19 BUYs and 0 SELLs from insiders. Insiders purchased 1,235,222 shares during that period but sold 0.

In the most recent transaction, Hall Justin bought 69,767 shares of NBY for 0.43 per share on Dec 06. After the transaction, the CEO, GC and Director now owns 73,172 company shares. In a previous transaction on Dec 06, Jones Andrew D. bought 36,765 shares at 0.44 per share. NBY shares that CFO owns now total 127,461.

Among the insiders who bought shares, Kunin Jeffrey acquired of 101,650 shares on Dec 03 at a per-share price of $0.46. This resulted in the President, DERMAdoctor, LLC holding 500,000 shares of NBY after the transaction. In another insider transaction, Kunin Audrey bought 101,650 shares at $0.46 per share on Dec 03. Company shares held by the Chief Product Officer now total 500,000.


The dividend paying company demonstrates a positive outlook for investors and helps them generate immediate cash.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for NBY in the last 3 months, the mean price target is $3.10 with high estimates of $4.00 and low estimates of $2.20. In terms of 52-week highs and lows, NBY has a high of $0.77 and a low of $0.17.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 2 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NBY is Buy with a score of 5.00. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.